GlobalData on MSN

Genmab reports top line results in Phase III DLBCL trial

Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival (PFS) for its subcutaneous bispecific ...
CURE

Epkinly Improves Progression-Free Survival in Relapsed/Refractory DLBCL

Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
Targeted Oncology

Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
Fierce Pharma

After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie ...
BioSpace

AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
Fierce Pharma

Incyte to seek FDA approval for 7-drug Monjuvi regimen in 1st-line diffuse large B-cell lymphoma

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi as a first-line treatment for diffuse large B-cell lymphoma (DLBCL). | A ...
Healio

VIDEO: A look at challenges, real-world treatment pathways in diffuse large B-cell lymphoma

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...
WFTV

Rep. Jamie Raskin cancer diagnosis: What is diffuse large-B cell lymphoma?

Raskin, D-Maryland, said in a statement that “After several days of tests, I have been diagnosed with Diffuse Large B Cell Lymphoma, which is a serious but curable form of cancer. “I am about to ...
Healio

Advancements, future research in diffuse large B-cell lymphoma treatment

Please provide your email address to receive an email when new articles are posted on . Ryan: The field of diffuse large B-cell lymphoma has seen tremendous advancements in the recent years, and that ...

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...